Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Inspecs CEO's pension buys £0.4m of shares

(Sharecast News) - Eyewear designer and producer Inspecs Group was in the green on Tuesday afternoon, after its chief executive officer's pension spent around £0.4m on shares. The company said Terra Firma Trust bought 850,053 shares across two transactions on Friday, at an average price of 47p.

It said the first transaction saw 833,333 shares purchased at a price of 47p, valuing it at £391,666.51.

The second transaction was for 16,720 shares at a price of 48.5p apiece, for a total of £8,109.20.

Inspecs said the Terra Firma Trust is the pension fund of its CEO Robin Totterman.

Following the purchases, it said Totterman and his connected persons had a beneficial interest in 18,625,005 of its shares, representing 18.3% of its issued capital.

At 1316 GMT, shares in Inspecs Group were up 16.54% at 55.94p.

Reporting by Josh White for

Share this article

Related Sharecast Articles

Director dealings: Blue Coast raises stake in Everyman Media
(Sharecast News) - Everyman Media revealed on Thursday that Blue Coast had acquired 50,000 ordinary shares in the AIM-listed cinema group.
Director dealings: Angus Energy CEO ups stake
(Sharecast News) - Angus Energy revealed on Wednesday that chief executive Richard Herbert had acquired 5.0m ordinary shares in the AIM-listed onshore oil and gas development firm.
Director dealings: Abrdn CEO makes share sale
(Sharecast News) - Abrdn revealed on Monday that chief executive Stephen Bird had disposed of 29,942 ordinary shares in the FTSE 250-listed global investment company.
Director dealings: Redx Pharma CEO ups stake
(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stage biopharmaceutical firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.